Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2017			10,000	9,484,000
Beginning Balance at Dec. 31, 2017	$ 50,189	$ 50,507	$ 0	$ 9	$ 433,044	$ (28)	$ (381,810)	$ (708)	$ (318)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(16,168)	(16,167)					(16,167)		(1)
Unrealized loss on marketable securities	(4)	(4)				(4)
Share-based compensation (in shares)				129,000
Share-based compensation	2,053	2,053		$ 0	2,053
Net proceeds from issuance of common stock (in shares)				176,000
Net proceeds from issuance of common stock	1,029	1,029		$ 1	1,028
Proceeds from option exercises (in shares)				77,000
Proceeds from option exercises	355	355		$ 0	355
Change in ownership in subsidiary	0	(47)			(47)				47
Ending Balance (in shares) at Dec. 31, 2018			10,000	9,866,000
Ending Balance at Dec. 31, 2018	37,454	37,726	$ 0	$ 10	436,433	(32)	(397,977)	(708)	(272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of accounting standard	(62)	(62)					(62)
Net loss	(19,352)	(19,361)					(19,361)		9
Unrealized loss on marketable securities	34	34				34
Share-based compensation (in shares)				94,000
Share-based compensation	1,165	1,165		$ 0	1,165
Net proceeds from issuance of common stock (in shares)				569,000
Net proceeds from issuance of common stock	$ 1,314	1,314		$ 1	1,313
Proceeds from option exercises (in shares)	240
Ending Balance (in shares) at Dec. 31, 2019			10,000	10,529,000
Ending Balance at Dec. 31, 2019	$ 20,553	$ 20,816	$ 0	$ 11	$ 438,911	$ 2	$ (417,400)	$ (708)	$ (263)